NCT07209488 Acquired Dyslexia Modeling and Treatment
| NCT ID | NCT07209488 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2025-12-03 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a low-risk, early phase 1, multicenter trial to test the use of a computational (neural network) cognitive model of reading to simulate acquired dyslexia and its treatment. The aim is to determine whether there is an advantage to receiving the treatment the model predicts to be advantageous compared to the alternative treatment. All participants will receive two full rounds of treatment. A round of treatment will consist of either phonomotor treatment (PMT) or semantic feature analysis (SFA) for 60 hours, distributed over 5 days a week for 2 hours a day.
Eligibility Criteria
Inclusion Criteria: * Fluent in English as a first language pre-stroke by self report. * Normal or corrected-to-normal vision. * Normal or aided hearing. * Left hemisphere ischemic or hemorrhagic stroke (as verified by a structural brain scan). * Impaired reading as confirmed by significant impairment in the Basic Skills cluster of the Woodcock Reading Mastery Test - III. Exclusion Criteria: * Diagnosed pre-stroke neurological disease affecting the brain other than left hemisphere stroke. * Severe apraxia of speech (determined by consensus judgment among speech-language pathologists). * History of learning disabilities such as developmental dyslexia or current self-reported major psychiatric disorders. * Inability to undergo, or provide a copy of, a post-stroke brain imaging scan.
Contact & Investigator
William W Graves, PhD
PRINCIPAL INVESTIGATOR
Rutgers, The State University of New Jersey
Frequently Asked Questions
Who can join the NCT07209488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07209488 currently recruiting?
Yes, NCT07209488 is actively recruiting participants. Contact the research team at william.graves@rutgers.edu for enrollment information.
Where is the NCT07209488 trial being conducted?
This trial is being conducted at Tallahassee, United States, Baltimore, United States, West Orange, United States.
Who is sponsoring the NCT07209488 clinical trial?
NCT07209488 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is William W Graves, PhD at Rutgers, The State University of New Jersey. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.